Studies showed that intravascular administration of MSCs reduced atherosclerosis in apolipoprotein E-deficient (ApoE−/−) mice and in low-density lipoprotein receptor-deficient (Ldlr−/−) mice [24, 25]. The gene discussed is APOE; the disease is atherosclerosis.